The emerging role of citrate as a diagnostic biomarker in SLC13A5-developmental and epileptic encephalopathy


Por: Nou-Fontanet L, Muñoz-Puga N, Madrigal I, Arca-Diaz G, Alonso-Colmenero I, Artuch-Iriberri R and Fons-Estupina C

Publicada: 1 abr 2026 Ahead of Print: 1 feb 2026
Resumen:
SLC13A5-developmental and epileptic encephalopathy (SLC13A5-DEE) is a rare autosomal recessive disorder characterized by neonatal-onset seizures, global developmental delay, and amelogenesis imperfecta. Diagnosis can be particularly challenging when genetic testing identifies variants of uncertain significance (VUS). To highlight the diagnostic value of citrate quantification in confirming SLC13A5-DEE. We report a female infant, born to consanguineous parents, who presented with refractory seizures at 14 hours of life. Partial seizure control was initially achieved with oxcarbazepine and lacosamide; however, complete seizure control occurred after the introduction of valproic acid. Brain MRI demonstrated punctate white matter abnormalities. Genetic testing identified a homozygous missense variant in SLC13A5 (c.1268G>A, p.Gly423Glu), classified as a VUS. Subsequently, biochemical analysis showed markedly elevated plasma citrate levels (820 mu mol/L; control values: 19-83), and increased urinary citrate excretion (5615 mmol/mol creatinine; control values: 162-2200), consistent with plasmatic membrane Na+-coupled citrate transporter dysfunction. The abnormally increased citrate levels supported the reclassification of the variant as likely pathogenic according to ACMG criteria (PP4). At 8 months of age, the patient remained seizure-free but exhibited mild developmental delay. This case underscores the diagnostic value of plasma and urinary citrate quantification as reliable and accessible biomarkers in the diagnostic workup of SLC13A5-DEE. Furthermore, early treatment with valproic acid may improve seizure control and potentially improve developmental outcomes.

Filiaciones:
:
 Early Onset and Genetic Epilepsy Program, Pediatric Neurology Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain

 Complex Epilepsies Research Group, Institut de Recerca de Sant Joan de Déu, Barcelona, Spain

:
 Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

 Clinical Biochemistry Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain

Madrigal I:
 Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, IDIBAPS (Institut de Investigacions Biomèdiques August Pi I Sunyer), Barcelona, Spain

Arca-Diaz G:
 Neonatology Department, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain

Alonso-Colmenero I:
 Neurophysiology Program, Pediatric Neurology Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain

 Complex Epilepsies Research Group, Institut de Recerca de Sant Joan de Déu, Barcelona, Spain

Artuch-Iriberri R:
 Clinical Biochemistry Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain

 Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

Fons-Estupina C:
 Complex Epilepsies Research Group, Institut de Recerca de Sant Joan de Déu, Barcelona, Spain

 Centre for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

 Early Onset and Genetic Epilepsy Program, Pediatric Neurology Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
ISSN: 12949361





EPILEPTIC DISORDERS
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ, Francia
Tipo de documento: Editorial Material
Volumen: 28 Número: 2
Páginas: 505-511
WOS Id: 001685844200001
ID de PubMed: 41664594

MÉTRICAS